Get to know our clinical trials

Clinical trial to analyze the efficacy of JNJ-55308942 in the treatment of bipolar depression

THE PURPOSE OF THIS STUDY IS TO TEST WHETHER JNJ-55308942 IS SAFE AND USEFUL FOR THE TREATMENT OF PATIENTS WITH BIPOLAR DEPRESSION AND TO COMPARE THE POSITIVE AND NEGATIVE EFFECTS OF JNJ-55308942 WITH THE POSITIVE AND NEGATIVE EFFECTS OF PLACEBO. THE PLACEBO LOOKS THE SAME AS JNJ-55308942 AND IS ADMINISTERED IN THE SAME MANNER, BUT CONTAINS NO ACTIVE INGREDIENT.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • RANDOMIZED, STRATIFIED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF JNJ-55308942 IN THE TREATMENT OF BIPOLAR DEPRESSION
  • Code EudraCT: 2021-004790-31
  • Protocol number: 55308942BIP2001
  • Promoter: Janssen-Cilag
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.